Novel heterocyclic hybrids of pyrazole targeting dihydrofolate reductase: design, biological evaluation and <i>in</i> <i>silico</i> studies
作者:Ismail M. M. Othman、Mohamed A. M. Gad-Elkareem、Abd El-Galil E. Amr、Mohamed A. Al-Omar、Eman S. Nossier、Elsayed A. Elsayed
DOI:10.1080/14756366.2020.1791842
日期:2020.1.1
Abstract A novel series of pyrazole analogues including hydrazones, pyrazolo[4,3-c]-pyridazines, pyrazolo[3,4-e][1,2,4]triazine and pyrazolo[3,4-d][1,2,3]triazoles was designed, synthesised and screened for their in vitro antimicrobial and DHFR inhibition activity. Compounds bearing benzenesulphonamide moiety incorporated with 3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene) hydrazine 3a or 6-amino-7-cyan
摘要 一系列新的吡唑类似物,包括,吡唑并[4,3- c ]-哒嗪,吡唑并[3,4- e ] [1,2,4]三嗪和吡唑并[3,4- d ] [1,2,设计,合成并筛选了3]三唑的体外抗菌和DHFR抑制活性。带有苯磺酰胺部分的化合物与3-甲基-5-氧代-1 H-吡唑-4(5 H)-亚烷基)肼3a或6-氨基-7-氰基-3-甲基-5 H-吡唑并入[4,3 - ç ]哒嗪6A分别显示出与环丙沙星和两性霉素B相当的优异抗菌活性和广谱抗菌活性,分别作为阳性抗生素和抗真菌对照。此外,与甲氨蝶呤(IC 50 = 0.14±1.25 µM)相比,这些衍生物被证明是最具活性的DHFR抑制剂,IC 50值为0.11±1.05和0.09±0.91 µM 。将在硅片研究,做计算新合成衍生物的类药性和毒性风险参数。另外,通过分子对接证实了带有磺酰胺的吡唑衍生物对DHFR的高效力,并且可以用作进一步修饰的最佳先导。